41526-30-1

Upstream product

• 590-28-3 potassium cyanate 
• 22094-69-5 N-(4-methoxyphenyl)glycine 
• 1566-42-3 p-anisidine urea 
• 105-39-5 chloroacetic acid ethyl ester 
• 1345028-56-9 C₁₁H₁₂N₂O₃ 
• 104-94-9 4-methoxy-aniline 
• 6092-47-3 ethyl (chloroacetyl)carbamate 

Downstream Products

• 1596360-45-0 methyl 6-[[3-(4-methoxyphenyl)-2,5-dioxo-imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxylate 
• 1314745-30-6 1-(4-methoxyphenyl)-2,4-dichloro-1H-imidazole-5-carbaldehyde 
• 1314745-43-1 1-(4-methoxyphenyl)-2-(4-tolyloxy)-4-chloro-1H-imidazole-5-carbaldehyde 
• 1314745-38-4 2-azido-1-(4-methoxyphenyl)-4-chloro-1H-imidazole-5-carbaldehyde 

Relevant academic research and scientific papers

Synthesis of novel imidazolidine-2,4-dione derivatives as potential antidiabetic agents

A series of novel imidazolidine-2,4-dione derivatives were synthesized and their chemical structures were confirmed by 1H NMR and ESI-MS. The preliminary antidiabetic screening results demonstrated that the compound 3b showed some antidiabetic activity and could acted as lead compound for further design and discovery of antidiabetic agents.

Highly efficient dialkylphosphate-mediated syntheses of hydantoins and a bicyclohydantoin under solvent-free conditions

Diversely substituted hydantoins have been synthesized by new strategy from cyanamide based precursor, that is, methyl N-cyano-N-alkyl/arylaminoacetate. Dialkylphosphates were employed as the mild reagent to hydrolyze and cyclize the substrate in one step to give quantitative yields of the desired products. Syntheses of multivalent hydantoins viz bis-hydantoin, bicyclohydantoin have potentially widened the scope and applicability of the present method. Solvent-free conditions and very easy work-up procedure make the reaction convenient and eco-friendly. Single crystal structures of some of the representative compounds are also reported.

Aryloxypropanolamine derivatives, pharmaceutical compositions and adrenegic thereof

Compounds having general formula I STR1 wherein R1 is hydrogen, lower alkyl, lower alkoxy, alkyl enoxy, halogen, cyano, carboxyamido or ureido group optionally separated from the phenyl ring by a methylene or ethylene bridge; R2 is hydrogen, halogen, lower alkyl or alkoxy; R3 is hydrogen, halogen, lower alkyl, lower alkoxy or R2 and R3, taken together, are a methylendioxy group; R4 is hydrogen or lower alkyl, endowed with remarkable cardioselective β-adrenolytic properties, are described. The process for their preparation and pharmaceutical compositions containing them are also described.